1292. Safety Profile of the Novel Siderophore Cephalosporin Cefiderocol in Randomized Phase 2 and Phase 3 Clinical Studies of Serious Gram-Negative Infections

BACKGROUND: Cefiderocol (CFDC), the first siderophore cephalosporin, is approved in the United States (complicated urinary tract infections [cUTI]) and Europe for the treatment of patients with Gram-negative (GN) infections with limited treatment options. METHODS: This analysis investigated the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsunaga, Yuko, Sonoyama, Takuhiro, Casanova, Luis, Nagata, Tsutae Den, Echols, Roger, De Gregorio, Fabio, Ogura, Eriko, Portsmouth, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776416/
http://dx.doi.org/10.1093/ofid/ofaa439.1475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776416/
http://dx.doi.org/10.1093/ofid/ofaa439.1475

Ejemplares similares